KM Research Hub

LITERATURE

符合新入排标准的活动候选

仅显示 v3 复核后仍在自动处理队列中的候选论文。 共 1896 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial.Lancet OncolPMID 42945979无 PMCID2026-Oct-270.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.LancetPMID 42933459无 PMCID2026-Oct-260.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.Ann OncolPMID 42933636PMC137187492026-Oct-260.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score ≥ 5%: results from the RATIONALE-305 trial.Qual Life ResPMID 42927580PMC136965562026-Oct-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study.Ann OncolPMID 42927853无 PMCID2026-Oct-250.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).Ann OncolPMID 42927854无 PMCID2026-Oct-250.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.Ann OncolPMID 42927855无 PMCID2026-Oct-250.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.Ann OncolPMID 42927856无 PMCID2026-Oct-250.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.N Engl J MedPMID 42929675无 PMCID2026-Oct-250.99Eligible primary Phase 3 randomized oncology drug trial with a time-to-event primary endpoint and reported original results.待处理
Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy.N Engl J MedPMID 42929693无 PMCID2026-Oct-250.98Eligible original Phase 3 randomized drug trial report in advanced NSCLC with time-to-event primary endpoint and reported Kaplan-Meier/hazard-ratio results.待处理
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.N Engl J MedPMID 42929694无 PMCID2026-Oct-250.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
COMPANION-002: A Randomized Phase II/III Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-Line Therapy in Patients With Advanced Biliary Tract Cancer.J Clin OncolPMID 42920414无 PMCID2026-Oct-240.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
ENZARAD (ANZUP 1303): Phase III Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.J Clin OncolPMID 42921729无 PMCID2026-Oct-240.98Eligible original Phase III randomized oncology drug trial reporting a primary time-to-event efficacy result.待处理
Short-Course Ruxolitinib Initiated at Neutrophil Engraftment for Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Randomized, Open-Label, Controlled Phase II Trial.Transplant Cell TherPMID 42926045无 PMCID2026-Oct-240.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.Ann OncolPMID 42926106无 PMCID2026-Oct-240.99Eligible as an original formal-result Phase III randomized oncology trial with drug intervention and time-to-event efficacy endpoints.待处理
A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.Ann OncolPMID 42926107无 PMCID2026-Oct-240.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.Ann OncolPMID 42926108无 PMCID2026-Oct-240.97Eligible: phase III randomized oncology drug trial reporting final overall survival time-to-event results.待处理
Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).Ann OncolPMID 42926109无 PMCID2026-Oct-240.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann OncolPMID 42926111无 PMCID2026-Oct-240.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.N Engl J MedPMID 42929692无 PMCID2026-Oct-240.98This is an original Phase 3 randomized oncology trial of drug interventions with time-to-event primary and key secondary efficacy endpoints, reporting formal results.待处理
Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.N Engl J MedPMID 42929702无 PMCID2026-Oct-240.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small-cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study.Ann OncolPMID 42918419无 PMCID2026-Oct-230.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial.Ann OncolPMID 42918420无 PMCID2026-Oct-230.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study.Ann OncolPMID 42918422无 PMCID2026-Oct-230.99Eligible original Phase III randomized oncology drug trial reporting a primary time-to-event efficacy endpoint (EFS) with hazard ratios and Kaplan-Meier-type survival estimates.待处理
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.Ann OncolPMID 42918423无 PMCID2026-Oct-230.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.Ann OncolPMID 42918424无 PMCID2026-Oct-230.95Eligible updated Phase III randomized drug trial report in human prostate cancer with OS/rPFS time-to-event efficacy results.待处理
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.JAMAPMID 42925007PMC136950782026-Oct-230.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.N Engl J MedPMID 42734213无 PMCID2026-Oct-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268).Radiother OncolPMID 42913944无 PMCID2026-Oct-220.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer.Nat CommunPMID 43052301PMC137825462026-Oct-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer.J Clin OncolPMID 42777180PMC136827232026-Oct-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of KRAS-Targeted Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: An Updated Systematic Review and Meta-Analysis of Pooled Proportions.Am J Clin OncolPMID 42956271无 PMCID2026-Oct-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.N Engl J MedPMID 42874102无 PMCID2026-Oct-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Interpretable Prediction of Lymphopenia Following Neoadjuvant Chemoradiotherapy for rectal Cancer: An Analysis of the ARISTOTLE randomized phase 3 Trial.Clin Oncol (R Coll Radiol)PMID 43019770无 PMCID2026-Oct-140.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial.Clin Lymphoma Myeloma LeukPMID 42971868无 PMCID2026-Oct-120.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO.Clin Lymphoma Myeloma LeukPMID 42998919无 PMCID2026-Oct-110.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review.Cancer Res TreatPMID 42845030无 PMCID2026-Oct-080.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Contemporary Chemotherapy Benchmarks for Molecularly Defined Advanced NSCLC: Reconstructed Individual Patient-Level Data of 22 Randomized Trials.LungPMID 42842004PMC136459422026-Oct-070.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Beyond Contraindication-Based Selection: The Unmet Need for Predictive Biomarkers in First-Line Immunotherapy for Advanced HCC.Target OncolPMID 42830371无 PMCID2026-Oct-040.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.LancetPMID 42702214无 PMCID2026-Oct-030.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.LeukemiaPMID 42827117无 PMCID2026-Oct-020.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.CancerPMID 42764731PMC135912012026-Oct-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Giredestrant plus Everolimus in Advanced Breast Cancer.N Engl J MedPMID 42814929PMC136746762026-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704.Int J Radiat Oncol Biol PhysPMID 42822544PMC136411792026-Oct-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial.Radiother OncolPMID 42570798无 PMCID2026-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.Int J Clin OncolPMID 42579028PMC136150082026-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel.Eur Urol OncolPMID 42595654无 PMCID2026-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial.Radiother OncolPMID 42604670无 PMCID2026-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.Br J HaematolPMID 42608172无 PMCID2026-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.Lung CancerPMID 42636548无 PMCID2026-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理